本周主题本周诺华相继引进Arrowhead 和舶望制药的siRNA 药物,行业关注度大幅提升。小核酸药物具有开发周期短、效果持久、研发成功率高、不易产生耐药性等优势,有望成为新一代热门研发方向。小核酸药物在基因层面进行调控,能够为目前无法治愈的严重遗传疾病提供开创性的治疗思路,已经在神经病变、心血管疾病的治疗方面展现出了巨大的潜力。得益于高特异性靶向肝的GalNac 技术的发展成熟,目前肝靶点药物...
Source Link本周主题本周诺华相继引进Arrowhead 和舶望制药的siRNA 药物,行业关注度大幅提升。小核酸药物具有开发周期短、效果持久、研发成功率高、不易产生耐药性等优势,有望成为新一代热门研发方向。小核酸药物在基因层面进行调控,能够为目前无法治愈的严重遗传疾病提供开创性的治疗思路,已经在神经病变、心血管疾病的治疗方面展现出了巨大的潜力。得益于高特异性靶向肝的GalNac 技术的发展成熟,目前肝靶点药物...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.